Back to Authors

Al‐Kali, Aref

https://orcid.org/0000-0002-0824-3715

A5008422091 | I1330342723

Mayo Clinic

Citations 400

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9019-9020

10.1182/blood-2022-168303

Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1286-1287

10.1182/blood-2022-165491

Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12238-12240

10.1182/blood-2022-165470

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2887-2890

10.1182/blood-2022-162367

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9735-9736

10.1182/blood-2022-163450

Prevalence and Impact of Clonal Hematopoiesis in Therapy Related Myeloid Neoplasms Occurring in the Context of Low-Grade Follicular Lymphoma Treated with Radioisotope Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11403-11405

10.1182/blood-2022-165124

U2AF1 Mutant Clonal Hematopoiesis Is Infrequent, Context Dependent, and Commonly Co-Occurs with BCOR Mutations

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11408-11409

10.1182/blood-2022-166794

Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6962-6963

10.1182/blood-2022-167978

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6964-6965

10.1182/blood-2022-168349

ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1112-1114

10.1182/blood-2022-156512